سعر امريبرومازيبام 1.5 مجم 30 قرص 2022

Bromazepam 1.5 mg tablets, pack of 30; benzodiazepine anxiolytic.

• Short-term symptomatic relief of manifestations of excessive anxiety in patients with anxiety neurosisPopulation: Adults (not recommended under 18 years)Health Canada Drug Product Database (product monograph PDF)

• Most frequent: drowsiness, ataxia and dizziness, mainly at the start of treatment. Others include headache, fatigue, confusion, mood changes, dry mouth, nausea, muscle weakness, blurred or double vision, rash, pruritus, incontinence, hypotension, palpitations, respiratory depression, dependence and withdrawal, and falls and fractures.International label, equivalent formulation · Health Canada Drug Product Database (product monograph PDF)

• Hypersensitivity to bromazepam, other benzodiazepines or any ingredient; myasthenia gravis; severe hepatic impairment; severe respiratory insufficiency; sleep apnea syndrome; narrow-angle glaucoma.International label, equivalent formulation · Health Canada Drug Product Database (product monograph PDF)

• Boxed warning: benzodiazepines can cause abuse, misuse, addiction, physical dependence and withdrawal reactions (which can be severe or life-threatening); assess risk before prescribing, monitor regularly, avoid abrupt discontinuation or rapid dose reduction and taper gradually.International label, equivalent formulation · Health Canada Drug Product Database (product monograph PDF)
• Boxed warning: concomitant use with opioids may cause profound sedation, respiratory depression, coma and death; reserve for patients without alternatives and limit doses and duration.International label, equivalent formulation · Health Canada Drug Product Database (product monograph PDF)
• Avoid alcohol and other CNS depressants; sedation, amnesia and impaired muscle function affect driving and operating machinery; anterograde amnesia and paradoxical reactions (agitation, aggression, hallucinations) may occur; not for primary treatment of depression or psychosis; increased risk of falls and fractures, especially in the elderly; use caution in chronic respiratory disease.International label, equivalent formulation · Health Canada Drug Product Database (product monograph PDF)

• OpioidsAdditive CNS depression: risk of profound sedation, respiratory depression, coma and death; reserve concomitant use for patients without alternatives, at minimum doses and duration.Health Canada Drug Product Database (product monograph PDF)
• Alcohol and other CNS depressants (hypnotics, antipsychotics, antihistamines, anticonvulsants, antidepressants, anesthetics, narcotic analgesics)Enhanced sedation and cardio-respiratory depression; avoid alcohol.Health Canada Drug Product Database (product monograph PDF)
• Cimetidine, propranololMay prolong the elimination half-life of bromazepam by reducing its clearance (cimetidine by about 50%).Health Canada Drug Product Database (product monograph PDF)

• Safety in pregnancy has not been established and bromazepam should not be used during pregnancy; benzodiazepine use in the first trimester has been associated with congenital malformations; women who plan or suspect pregnancy should consult their physician about stopping.International label, equivalent formulation · Health Canada Drug Product Database (product monograph PDF)
• Bromazepam and its metabolites are probably excreted in human milk; it should not be given to nursing mothers.International label, equivalent formulation · Health Canada Drug Product Database (product monograph PDF)

English text not available for this section.